Sufentanil: a risk factor for lactic acidosis in patients after heart valve surgery

Table 1 Patients, Preoperative and Inoperative Characteristics and Descriptive Data and results of univariate analysis and chi-square test

Variable	Lactic acidosis group (n = 38)	Control group (n = 177)	P
Female	21 (55.2)	79 (44.6)	0.28
Age (years)	57.65 ± 9.27	53.79 ± 13.53	0.1
Body surface area (m²)	1.72 ± 0.1	1.72 ± 0.22	0.85
Main preoperative diagnosis (case)
RHD	33	133
DHVD	3	42
IE	2	2
Preoperative diabetes mellitus	3	24	0.26
Preoperative atrial ibirllation fibrillation	12	40	0.17
Preoperative hypertension	10	45	0.53
Operative method
MVP + TVP	6	33
MVP	0	5
MVP + AVR	0	1
MVR + TVP	24	123
AVR	2	13
MVR + AVR + TVP	6	2
Preoperative EF value (%)	60 (50.75, 62.75)	62 (60, 67)	0.01
Preoperative left ventricle (end-diastolic diameter cm)	54 (50.75, 56)	51 (48, 55)	0.02
Cardiopulmonary bypass time (min)	140.05 ± 60.05	117.05 ± 57.45	< 0.001
Aortic occlusion time (min)	104 ± 46.76	84.20 ± 43.83	< 0.001
Total operation time (min)	240 (180, 300)	240 (205, 300)	0.79
Total sufentanil dosage (µg)	545.26 ± 163.05	478.13 ± 146.51	0.01
Relative sufentanil infusion rate (µg.kg-1.h-1)	2.15 ± 0.8	1.83 ± 0.60	0.03
8 h mean blood glucose level(mmol/L)	15.37 ± 2.87	12.79 ± 2.01	0.19
Infusion rate of propofol(mg/kg.h)	7 (6.6, 8.4)	6.9 (6.5, 8)	0.95
8 h Total dopamine dosage(mg)	166.8 (118.4, 174.6)	158.4 (129.6, 184.3)	0.89
8 h Total Epinephrine dosage(mg)	7 (18.4)	38 (21.4)	0.67

Data are presented as numbers, the mean ± standard deviation or median (interquartile range). Abbreviations: RHD, rheumatic heart disease; DHVD, degenerative heart valvular disease; IE, infective endocarditis; MVP, mitral valvuloplasty; MVR, mitral valve replacement; TVP, tricuspid valve replacement; AVR, aortic valve replacement. Among the patients, 52 also presented with atrial fibrillation before surgery, 45 of whom underwent radiofrequency ablation (Maze IV)

ISSN: 1749-8090